Stocks · News reference
8-K filing — Ultragenyx Pharmaceutical Inc. (RARE)
Filed: 2026-10-14 AccNo: 0001193125-26-421079 Size: 149 KB Item 1.01: Entry into a Material Definitive Agreement
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV
Ultragenyx Gene Therapy For MPS IIIA Clears EMA Validation, Holds PRIME And Orphan Designations, Will Fall Under EU Joint Clinical Assessment